University of Houston Receives $3.9M NIH Grant to Develop First Treatment for Deadly Cryptosporidium Infections
核心洞察
University of Houston's Gregory Cuny received nearly $4 million from the National Institute of Allergy and Infectious Diseases to develop treatments for Cryptosporidium (搜索) infections, which currently have no effective cure.
Cryptosporidium (搜索) parasites kill over 50,000 children under five annually through severe diarrhea and represent the second leading cause of diarrhea-related death after rotavirus.
The research targets CDPK1 (搜索) enzyme, which is essential for parasite survival, with drug candidates designed for gastrointestinal targeting through enterohepatic recycling.
The University of Houston has secured nearly $4 million in funding from the National Institute of Allergy and Infectious Diseases to develop the first effective treatments for Cryptosporidium (搜索) infections, a deadly waterborne disease that currently has no cure. Gregory Cuny, the Joseph P. & Shirley Shipman Buckley Endowed Professor of Drug Discovery, will lead the multi-institutional translational research effort.
Addressing a Critical Global Health Gap
Cryptosporidium (搜索) protozoan parasites rank among the world's most dangerous waterborne pathogens, with the species C. hominis and C. parvum claiming over 50,000 lives annually among children under five years old who die from severe diarrhea. The parasites represent the second leading cause of diarrhea-related death after rotavirus and pose fatal risks to immunocompromised adults.
The pathogen's potential for bioterrorism adds another layer of concern, as these parasites could be deliberately introduced into water supplies, earning them classification as a Center for Disease Control Class B bioterrorism agent. Despite this significant threat, Cryptosporidium (搜索) stands alone among the top four diarrheal pathogens with no effective treatments or vaccines available.
Targeting Essential Parasite Enzyme
The research focuses on CDPK1 (搜索) (Calcium dependent protein kinase 1 (搜索)), an enzyme essential for Cryptosporidium (搜索) survival that has emerged as an attractive therapeutic target. Scientific evidence demonstrates that silencing CDPK1 significantly reduces parasite growth, making it a promising avenue for drug development.
"Our long-term goal is to identify clinical candidates that can be advanced in our effort to establish CDPK1 (搜索) as a validated drug target for treatment of Cryptosporidium (搜索)-induced infections," said Cuny.
Innovative Drug Design Strategy
The research team plans to engineer drug candidates using enterohepatic recycling, a process designed to keep medications in the system longer by having them absorbed through the liver and then sent to the intestine rather than being eliminated. This approach aims to maximize therapeutic effectiveness while minimizing systemic exposure.
The drugs are being specifically designed to target the gastrointestinal tract directly, where Cryptosporidium (搜索) infections primarily occur. This targeted delivery system could reduce side effects while ensuring the medication reaches the site of infection.
"CDPK1 (搜索) has structural features that present opportunities for selective inhibitor design targeting the parasite kinase enzyme without harming similar human enzymes," explained Cuny. "Demonstrating GI-targeting would also be highly significant to drug design strategies for other GI conditions, such as colonic cancers and inflammatory bowel diseases."
Multi-Institutional Collaboration
The research effort brings together expertise from multiple institutions. Cuny's team includes Ming Hu, Diana Shu-Lian Chow Endowed Professor of Drug Discovery and Development at UH; Kevin Garey, Robert L. Boblitt Endowed Professor of Drug Discovery at UH; Wesley Van Voorhis from the University of Washington; and Saul Tzipori from Tufts University.
The collaborative approach aims to develop effective drugs urgently needed to manage cryptosporidiosis (搜索) in young children, immunocompromised adults, and as a countermeasure to epidemic outbreaks, addressing a critical gap in global health preparedness.